China Medicine Inc – Trademark Portfolio
Entity Type: 03
China Medicine Inc holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 6 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include ACUBABY, FERTIOLOGIST, and FERTILITY EXPRESS. The owner is based in Chicago, IL.
333 North Michigan Ave
Suite 818
Chicago, IL 60601
Showing of trademarks Trademarks
Trademark Classifications
China Medicine Inc's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does China Medicine Inc have?
China Medicine Inc has 6 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 abandoned, 1 cancelled.
What trademark classes does China Medicine Inc file in?
China Medicine Inc files trademarks across 3 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are China Medicine Inc's most well-known trademarks?
China Medicine Inc's registered trademark portfolio includes well-known marks such as ACUBABY, FERTIOLOGIST, and FERTILITY EXPRESS. These are among 4 currently registered trademarks in the portfolio.
What is China Medicine Inc's trademark registration success rate?
China Medicine Inc has a 67% trademark registration rate, with 4 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.